5.3455  0.646 (13.73%)		11-05 11:17
Open: 4.61 High: 5.55 Volume: 158,651		Pre. Close: 4.7 Low: 4.61 Market Cap: 4(M)

Short term
Mid term
Targets	6-month :	41.75	1-year :	64.23
Resists	First :	35.75	Second :	55
Pivot price	9.79
Supports	First :	4.61	Second :	3.83
MAs	MA(5) :	5.48	MA(20) :	11.65
	MA(100) :	11.54	MA(250) :	22.42
MACD	MACD :	-2	Signal :	-1.1
%K %D	K(14,3) :	1	D(3) :	0.4
RSI	RSI(14): 42
52-week	High :	117.5	Low :	4.61

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GNPX ] has closed above bottom band by 28.7%. Bollinger Bands are 111.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 15 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	5.21 - 5.26	5.26 - 5.29
Low:	4.53 - 4.59	4.59 - 4.62
Close:	4.63 - 4.73	4.73 - 4.79

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Tue, 04 Nov 2025
Genprex (GNPX) Receives European Patent Intent for Cancer Gene T - GuruFocus

Tue, 04 Nov 2025
Genprex Announces European Patent Intent for Reqorsa® Gene Therapy - TradingView

Tue, 04 Nov 2025
Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer (2025-11-04) - Seeking Alpha

Tue, 04 Nov 2025
Genprex (NASDAQ: GNPX) gets EPO intent to grant patent for REQORSA+PD-1 in cancer - Stock Titan

Thu, 23 Oct 2025
Genprex (NASDAQ: GNPX) expects $2.7M upfront; up to $5.4M more from short-term warrants - Stock Titan

Thu, 23 Oct 2025
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	1 (M)
Shares Float	1 (M)
Held by Insiders	0.2 (%)
Held by Institutions	1.5 (%)
Shares Short	45 (K)
Shares Short P.Month	83 (K)

EPS	42.5
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.09
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-207.5 %
Return on Equity (ttm)	-612.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-17.31
Qtrly Earnings Growth	0 %
Operating Cash Flow	-13 (M)
Levered Free Cash Flow	-9 (M)

PE Ratio	0.12
PEG Ratio	0
Price to Book value	2.56
Price to Sales	0
Price to Cash Flow	-0.41

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.